#USA #New York #Class Action #Securities Fraud #ADMA Biologics

ADMA Biologics Faces Legal Challenges Over Alleged Revenue Misrepresentation

In recent developments, ADMA Biologics, a publicly traded company known for its advanced immunotherapies, is finding itself under the scrutiny of investors and legal experts due to allegations of securities fraud. A report from Culper Research has stirred the waters by claiming that the company's revenue figures for 2025 were grossly inflated. The report asserts that while ADMA published a growth of 20%, the actual revenue had declined by approximately 3% year-over-year.

The revelations came just after ADMA Biologics announced its new revenue guidance for 2026, forecasting total revenues to reach at least $635 million, an increase from previous estimates of $630 million and $625 million. Investors are raising concerns regarding the accuracy of these forecasts considering the allegations surrounding the company's prior financial performance. During earnings calls throughout 2025, CEO Adam Grossman repeatedly emphasized a vision of accelerated growth driven by the successful utilization of their flagship product, ASCENIV, and the broader immunoglobulin portfolio. However, the authenticity of these claims is now under intense investigation.

The allegations suggest that ADMA may have resorted to dubious accounting practices, such as channel-stuffing and undisclosed related-party transactions, to present an impressive financial picture to investors. Following the publication of the Culper Research report on March 24, 2026, ADMA's shares took a sharp blow, dropping over 29% in just two days. On March 23, the stock closed at $13.59 but fell to $9.63 by March 25, sending ripples throughout the investment community.

As of now, law firm Levi & Korsinsky is leading an investigation to determine if ADMA Biologics misled investors by failing to disclose pressure on revenues and costs that would significantly influence the outlook for the company. Investors who have experienced financial losses due to fluctuations in ADMA shares are encouraged to take action. They can gather necessary documentation such as brokerage records outlining purchase dates and losses incurred to discuss their legal options.

A key aspect of this case is the role of the lead plaintiff in a class action lawsuit. The lead plaintiff is typically an investor with significant losses, appointed by the court to oversee the case on behalf of all affected parties. Individuals who have sold their shares at a loss may still be eligible to participate in the lawsuit, as eligibility is determined by the purchase dates rather than current ownership.

The timeline is crucial, as statements made by ADMA management during the 2025 earnings calls are being central to the investigation. Analysts and shareholders alike will be looking for clarity on the company's earnings reports and whether these misrepresentations were intentional or negligent.

For potential participants in the lawsuit, it is essential to act quickly. Levi & Korsinsky offers a free evaluation, which outlines the next steps investors can take to protect their rights. The firm has previously handled cases involving similar allegations of securities fraud, indicating their capability in navigating complex financial litigation.

In summary, ADMA Biologics is now at a crossroads, as the company's future hinges on how it addresses these revenue reporting issues. As investigations develop, shareholders are left to ponder the reliability of the firm’s assurances and what this means for their investments moving forward. If you are an investor who has been impacted, it is crucial to stay informed and ready to take action as the situation evolves.